相关实验视频

Updated: Jan 13, 2026

Exploring Biomolecular Interaction Between the Molecular Chaperone Hsp90 and Its Client Protein Kinase Cdc37 using Field-Effect Biosensing Technology

Exploring Biomolecular Interaction Between the Molecular Chaperone Hsp90 and Its Client Protein Kinase Cdc37 using Field-Effect Biosensing Technology

Published on: March 31, 2022

使用生化和计算方法对SHP2-Fumosorinone相互作用的表征

Jun Zhang¹, Lei Li², Ning Yang²

¹College of Life Sciences, Institute of Life Science and Green Development and Hebei Innovation Center for Bioengineering and Biotechnology, Hebei University, Baoding, China; State Key Laboratory of Synthetic Biology and Frontiers Science Center for Synthetic Biology; Tianjin Key Laboratory for Modern Drug Delivery & High-Efficiency; School of Pharmaceutical Science and Technology, Faculty of Medicine, Tianjin University, Tianjin, China.

Biochemical and biophysical research communications

|January 8, 2026

概括

富莫索里 (FU) 是一种新型,强效的Src同源性2 (SH2) 域含有蛋白质氨酸酸酶-2 (SHP2) 的抑制剂. 这种天然化合物直接与SHP2结合,为开发向癌症治疗提供了新的途径.

科学领域:

生物化学生物化学
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

SHP2酸酶是癌细胞增殖和瘤微环境的关键调节者.
SHP2是瘤学中验证的治疗点,最近开发了特定的抑制剂.
酸酶的"不可抗药"性质正受到新型抑制剂发现的挑战.

研究的目的:

确定和描述SHP2.2的新型抑制剂.
为了阐明在SHP2.2上Fumosorinone (FU) 的作用机制和结合部位.
为开发新的SHP2-向抗癌剂提供分子基础.

主要方法:

酶测试以确定FU对全长SHP2及其催化域的抑制常量 (IC50).
异热定位热量计 (ITC) 验证FU与SHP2 PTP域的直接结合.
分子对接模拟以预测FU相互作用的结合点和模式.

主要成果:

富莫索里 (FU) 抑制了全长的SHP2 (IC50 = 38μM) 和其孤立的PTP域 (IC50 = 1.4μM).
加强PTP域的抑制表明SH2域阻碍了FU进入全长酶.
ITC证实了FU与PTP域的直接结合;分子对接揭示了PTP表面的一个口袋中的全oster抑制机制.

结论:

富莫索里 (FU) 是一种强效的非竞争性SHP2抑制剂,具有全性作用模式.
N端的SH2域调节了FU对催化PTP域的访问.
FU定义的结合部位和机制为设计新型SHP2向癌症疗法提供了基础.

关键词:

癌症治疗治疗癌症治疗烟雾氨酸之一抑制剂的抑制剂在 SHP2 中, SHP2 是 SHP2.

更多相关视频

Studies of Chaperone-Cochaperone Interactions using Homogenous Bead-Based Assay

Studies of Chaperone-Cochaperone Interactions using Homogenous Bead-Based Assay

Published on: July 21, 2021

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

相关概念视频

Protein-Drug Binding: Mechanism and Kinetics

Protein-Drug Binding: Mechanism and Kinetics

Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...

Protein-protein Interfaces

Protein-protein Interfaces

Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...